Eli Lilly's diabetes and weight-loss drug, Mounjaro (tirzepatide), has witnessed a remarkable surge in sales in India, marking a significant entry into the country's growing market for obesity and diabetes treatments. Launched in March 2025, Mounjaro has already achieved sales of approximately ₹24 crore within its first three months, with a notable 60% increase in sales from April to May. This rapid growth underscores the increasing demand for effective weight management and diabetes solutions in India.

Mounjaro's active ingredient, tirzepatide, is the first dual-target therapy approved for managing blood sugar levels and aiding weight reduction. It functions by activating both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors in the body. This dual action helps regulate blood sugar and promotes weight loss, positioning Mounjaro as a valuable treatment option for individuals with type 2 diabetes and obesity.

The drug is administered via subcutaneous injection once a week and is currently available in two strengths: 2.5 mg and 5 mg. In India, Mounjaro is priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial. A month's treatment can therefore cost between ₹14,000 to ₹17,500, depending on the dosage.

Data indicates that many patients are upgrading to the higher 5 mg dose after starting with the 2.5 mg dose, which aligns with standard medical recommendations to increase the dosage after one month, depending on the patient's tolerance and response. This trend is reflected in the sales figures, with the 5 mg injections experiencing a more substantial increase in sales compared to the 2.5 mg injections.

Several factors contribute to Mounjaro's rising popularity in India. Firstly, there is a growing awareness and concern about obesity and diabetes in the country. Studies suggest a significant percentage of India's urban population is classified as obese or overweight, making it a critical health issue. Secondly, Mounjaro's effectiveness in both managing blood sugar and promoting weight loss makes it an appealing option for individuals seeking comprehensive treatment. Finally, Eli Lilly's early launch of Mounjaro in India has given it a first-mover advantage in a rapidly expanding market.

However, despite the promising early results, some concerns remain. Experts have noted the importance of considering the long-term efficacy and potential side effects of Mounjaro, as well as its affordability for the broader Indian population. Nevertheless, with the increasing prevalence of diabetes and obesity in India, medications like Mounjaro could provide a much-needed remedy for a significant number of people. Other pharmaceutical companies are expected to launch similar products in India soon, intensifying competition in this expanding market.